3d
AllAfrica.com on MSNAfrica: Slow Uptake of Digital Tools Hampers Breakthroughs for African HealthcareGuest Column - The recent loss of funding in African healthcare is driving the medical fraternity to rethink solutions for accessible medical care for all Africans. On the 11th of, I spoke at the 15th ...
A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
A mom who was diagnosed with stage four cervical cancer claims doctors said her blood clot symptoms were “just your period.” ...
6d
News Medical on MSNScottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancerRegeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Cervical cancer symptoms can be subtle, so knowing the signs like unusual discharge, pain during sex, unexplained weight loss ...
Feb. 18, 2025 — The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study ...
It’s that lifelong passion that fueled his determination to overcome a cancer diagnosis as a teen. The third-generation drag racer was born into speed, following in the tracks of his father and ...
We are a world-leading cancer research institute, a charity, and a member institution of the University of London. Public donations and clinical partnerships are helping us to make the discoveries ...
New data out Friday showed retail sales declined more than expected in the first month of 2025. Headline retail sales fell 0.9% in January, more than the 0.2% decline economists had expected ...
The NFL had its fair share of surprises in 2024, starting with the Minnesota Vikings winning 14 games and the Washington Commanders making the conference championship game for the first time since ...
Data from the TROPION-Lung02 reported at the World Congress on Lung Cancer (WCLC) showed an overall response rate of 37% when DS-1062 (datopotamab deruxtecan) was combined with Merck & Co's PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results